Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-2
Sponsor: Rapport Therapeutics Inc.
Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
312
Start Date
2026-09-01
Completion Date
2029-09
Last Updated
2026-11-20
Healthy Volunteers
No
Conditions
Interventions
RAP-219
RAP-219 medium dose tablets administered orally daily
RAP-219
RAP-219 low dose tablets administered orally daily
Placebo
Matching placebo tablets administered orally
Locations (17)
Clinical Study Center
Huntsville, Alabama, United States
Clinical Study Center
Bentonville, Arkansas, United States
Clinical Study Center
Colorado Springs, Colorado, United States
Clinical Study Center
Maitland, Florida, United States
Clinical Study Center
Miami, Florida, United States
Clinical Study Center
Honolulu, Hawaii, United States
Clinical Study Center
Chicago, Illinois, United States
Clinical Study Center
Omaha, Nebraska, United States
Clinical Study Center
New York, New York, United States
Clinical Study Center
Raleigh, North Carolina, United States
Clinical Study Center
Portland, Oregon, United States
Clinical Study Center
Nashville, Tennessee, United States
Clinical Study Center
Houston, Texas, United States
Clinical Study Center
Melbourne, Australia
Clinical Study Center
Seoul, South Korea
Clinical Study Center
Cornwell, United Kingdom
Clinical Study Center
London, United Kingdom